Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion description "[Although anti-CD19 CAR T cells are at an early stage of development, the potent antigen-specific activity observed in patients suggests that infusions of anti-CD19 CAR T cells might become a standard therapy for some B-cell malignancies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion evidence source_evidence_literature NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion SIO_000772 23546520 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion wasDerivedFrom befree-20150227 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_assertion wasGeneratedBy ECO_0000203 NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.
- befree-20150227 importedOn "2015-02-27" NP1005005.RAUahipGL_EtQI2Abja_t3c2f27FO-nRNYKvlTy2qaOtY130_provenance.